Literature DB >> 25532439

Insights into the pathogenesis of GvHD: what mice can teach us about man.

J Hülsdünker1, R Zeiser.   

Abstract

Acute graft-vs-host disease (GvHD) is a life-threatening complication of allogeneic hematopoietic cell transplantation (allo-HCT). Most of the knowledge about the biology of GvHD is derived from mouse models of this disease and therefore a critical analysis of potential advantages and disadvantages of the murine GvHD models is important to classify and understand the findings made in these models. The central events leading up to GvHD were characterized in three phases which includes the tissue damage-phase, the T cell priming-phase and the effector-phase, when the disease becomes clinically overt. The role of individual cytokines, chemokines, transcription factor or receptors was studied in these models by using gene deficient or transgenic mice in the donor or recipient compartments. Besides, numerous studies have been performed in these models to prevent or treat GvHD. Several recent clinical trials were all based on previously reported findings from the mouse model of GvHD such as the trials on CCR5-blockade, donor statin treatment, vorinostat treatment or adoptive transfer of regulatory T cells for GvHD prevention. The different mouse models for GvHD and graft-vs-leukemia effects are critically reviewed and their impact on current clinical practice is discussed.
© 2014 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  T cells; animal models; cytokines; graft-vs-host disease; in vivo imaging; innate lymphoid cells; macrophages; neutrophils

Mesh:

Substances:

Year:  2014        PMID: 25532439     DOI: 10.1111/tan.12497

Source DB:  PubMed          Journal:  Tissue Antigens        ISSN: 0001-2815


  18 in total

Review 1.  The potential of non-myeloablative heterochronous autologous hematopoietic stem cell transplantation for extending a healthy life span.

Authors:  Primož Rožman
Journal:  Geroscience       Date:  2018-06-14       Impact factor: 7.713

2.  Update of humanized animal disease models in studying Graft-versus-host disease.

Authors:  Feng Huang; Feng Lin Cao; Song Guo Zheng
Journal:  Hum Vaccin Immunother       Date:  2018-09-05       Impact factor: 3.452

3.  Cytotoxic T lymphocyte antigen-4 regulates development of xenogenic graft versus host disease in mice via modulation of host immune responses induced by changes in human T cell engraftment and gene expression.

Authors:  Chunxu Gao; Debra Gardner; Marie-Clare Theobalds; Shannon Hitchcock; Heather Deutsch; Chidozie Amuzie; Matteo Cesaroni; Davit Sargsyan; Tadimeti S Rao; Ravi Malaviya
Journal:  Clin Exp Immunol       Date:  2021-09-22       Impact factor: 4.330

4.  Humanized Mouse Model to Study the P2X7 Receptor in Graft-Versus-Host Disease.

Authors:  Debbie Watson; Sam R Adhikary; Peter Cuthbertson; Nicholas J Geraghty; Katrina M Bird; Amal Elhage; Chloe Sligar; Ronald Sluyter
Journal:  Methods Mol Biol       Date:  2022

5.  Unique patterns of CD8+ T-cell-mediated organ damage in the Act-mOVA/OT-I model of acute graft-versus-host disease.

Authors:  Barbara Érsek; Nikolett Lupsa; Péter Pócza; Anett Tóth; Andor Horváth; Viktor Molnár; Bence Bagita; András Bencsik; Hargita Hegyesi; András Matolcsy; Edit I Buzás; Zoltán Pós
Journal:  Cell Mol Life Sci       Date:  2016-04-30       Impact factor: 9.261

6.  TAK1 inhibition ameliorates survival from graft-versus-host disease in an allogeneic murine marrow transplantation model.

Authors:  Ayako Kobayashi; Shinichi Kobayashi; Kosuke Miyai; Yukiko Osawa; Toshikatsu Horiuchi; Shoichiro Kato; Takaaki Maekawa; Takeshi Yamamura; Junichi Watanabe; Ken Sato; Hitoshi Tsuda; Fumihiko Kimura
Journal:  Int J Hematol       Date:  2017-10-12       Impact factor: 2.490

7.  Type 2 innate lymphoid cells treat and prevent acute gastrointestinal graft-versus-host disease.

Authors:  Danny W Bruce; Heather E Stefanski; Benjamin G Vincent; Trisha A Dant; Shannon Reisdorf; Hemamalini Bommiasamy; David A Serody; Justin E Wilson; Karen P McKinnon; Warren D Shlomchik; Paul M Armistead; Jenny P Y Ting; John T Woosley; Bruce R Blazar; Dietmar M W Zaiss; Andrew N J McKenzie; James M Coghill; Jonathan S Serody
Journal:  J Clin Invest       Date:  2017-04-04       Impact factor: 14.808

Review 8.  Cancer models in preclinical research: A chronicle review of advancement in effective cancer research.

Authors:  Humna Sajjad; Saiqa Imtiaz; Tayyaba Noor; Yusra Hasan Siddiqui; Anila Sajjad; Muhammad Zia
Journal:  Animal Model Exp Med       Date:  2021-03-29

9.  Ocular Graft-versus-Host Disease in a Chemotherapy-Based Minor-Mismatch Mouse Model Features Corneal (Lymph-) Angiogenesis.

Authors:  Uta Gehlsen; Daniela Stary; Martina Maass; Katarina Riesner; Gwen Musial; Michael E Stern; Olaf Penack; Philipp Steven
Journal:  Int J Mol Sci       Date:  2021-06-08       Impact factor: 5.923

10.  Comparative Analysis of Protocols to Induce Human CD4+Foxp3+ Regulatory T Cells by Combinations of IL-2, TGF-beta, Retinoic Acid, Rapamycin and Butyrate.

Authors:  Angelika Schmidt; Matilda Eriksson; Ming-Mei Shang; Heiko Weyd; Jesper Tegnér
Journal:  PLoS One       Date:  2016-02-17       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.